Blood tests reveal how leukemia drug works in patients

NCT ID NCT07243483

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how the drug venetoclax behaves in the bodies of 100 adults with acute myeloid leukemia (AML). Researchers will take extra blood samples to measure drug levels and see how they relate to treatment success. The study does not change the patient's regular care and involves only minimal extra blood draws.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CHU de Grenoble

    RECRUITING

    Grenoble, 38000, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • CHU de Saint-Étienne

    RECRUITING

    Saint-Etienne, 42100, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Centre Hospitalier Pierre Oudot

    RECRUITING

    Bourgoin, France, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Centre Leon Berard

    RECRUITING

    Lyon, 69008, France

    Contact Email: •••••@•••••

  • Hôpitaux Nord-Ouest - Villefranche-sur-Saône

    RECRUITING

    Villefranche-sur-Saône, 69400, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••